We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





HEMCO Corporation’s MicroFlow I Ductless Workstation Ensures Safety Comes First

By LabMedica International staff writers
Posted on 29 May 2020
Amidst the current pandemic, laboratory biosafety related to the coronavirus has assumed significant importance for laboratories and stakeholders involved in COVID-19 laboratory work.

HEMCO Corporation (Independence, MO, USA), a leading manufacturer of innovative laboratory equipment since 1958, is uniquely qualified to provide laboratory planning solutions due to its many years of experience. More...
The company manufactures and distributes laboratory fume hoods, casework, vented enclosures, modular clean labs, and laboratory safety equipment, as well as laboratory planning solutions to sciences and research and development technology industries.

The MICROFLOW I from HEMCO is a ductless, carbon filtered, rust resistant workstation equipped with activated carbon filtration, designed to collect small amounts of non-hazardous fumes and odors. The workstation is completely self contained and can be easily moved from station to station. It comes with an integral recessed work surface to contain spills and a clear hood surround with safety viewing sash for users. Sash can be conformed for use with a microscope, and variable speed fan control provides the option of high and medium speeds, orlow flow for sensitive operations. The MICROFLOW I operates on 115v AC, or 230v international, and conforms to UL, CSA, and CE requirements.

Related Links:
HEMCO Corporation


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Online QC Software
Acusera 24•7
Hematology Consumables
Bioblood Devices
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.